As Incyte Corporation’s recently-minted Opzelura gets off to the races in eczema, the drug has run up against a setback in another dermatology indication. The FDA has delayed its decision on Incyte’s ...

Incyte’s Opzelura picked up an approval from the Food and Drug Administration for use in patients with vitiligo Monday, making it the only approved therapy for the pigmentation disease in the U.S.

The US Food and Drug Administration (FDA) has approved Incyte’s Opzelura (ruxolitinib) cream 1.5% for the topical treatment of non-segmental vitiligo in adult and paediatric patients 12 years of age ...

Phase 3 data supporting the approval show treatment with Opzelura resulted in improvements in facial and total body repigmentation Fifty-two week data demonstrate continued improvements in ...

Opzelura (ruxolitinib) Cream is the first approved treatment in the European Union (EU) to address repigmentation in non-segmental vitiligo Phase 3 data supporting the approval show treatment with ...

As Incyte awaits the FDA’s decision on a second dermatology use for eczema newcomer Opzelura, the company is rolling out fresh 52-week data showing the benefits of its topical JAK inhibitor increase ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Data served as basis for recent FDA approval of ruxolitinib cream (Opzelura™) 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older ...

New York, USA, Feb. 28, 2025 (GLOBE NEWSWIRE) -- OPZELURA Continues to Revolutionize the Dermatology Market with Strong Market Uptake | DelveInsight OPZELURA (ruxolitinib cream) has shown strong ...

LEATHERHEAD, England--(BUSINESS WIRE)-- Incyte Biosciences UK today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Opzelura® ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) ...